Who Paid My Doc
Jeffrey Lee
Houston, TX Medical Doctor
NPI 1336125087 CMS profile 1298461
1140 Business Center Dr, Suite 570, Houston, TX 77043
General payments
$1,115
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jeffrey Lee of Houston, TX is reported in the CMS Open Payments database as having received $1,115 across 48 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $82 | 4 | |
| 2024 | General | $94 | 5 | |
| 2023 | General | $383 | 19 | |
| 2022 | General | $398 | 14 | |
| 2021 | General | $158 | 6 |
Beside peers
- Jeffrey Lee
- Texas median
- Middle half of Texas
- National median
In program year 2025, general payments to Jeffrey Lee were reported at $82. Among 86,592 Texas profiles paid that year, the median was $188 and the middle half received between $55 and $669.
Show as a table
| Year | Jeffrey Lee | Texas median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $191 | $56–$744 | $163 |
| 2020 | $0 | $125 | $38–$452 | $114 |
| 2021 | $158 | $150 | $43–$543 | $132 |
| 2022 | $398 | $169 | $50–$606 | $149 |
| 2023 | $383 | $183 | $53–$639 | $160 |
| 2024 | $94 | $188 | $55–$666 | $164 |
| 2025 | $82 | $188 | $55–$669 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 52 drugsPart D claims
1,727
Drug cost
$60,800
Branded share of claims
23.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 87 | $31,989 | |
| Myrbetriq Mirabegron | Brand | 32 | $8,493 | |
| Rytary Carbidopa/Levodopa | Brand | 14 | $3,401 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 14 | $1,452 | |
| Gabapentin | Generic | 74 | $1,172 | |
| Levothyroxine Sodium | Generic | 158 | $1,123 | |
| Irbesartan | Generic | 22 | $753 | |
| Potassium Chloride | Generic | 64 | $719 | |
| Quetiapine Fumarate | Generic | 46 | $708 | |
| Tamsulosin Hcl | Generic | 72 | $667 |
The 10 drugs with the highest cost, of 52 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,814 Part D prescribers listed as Geriatric Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$12,857
Medicare patients
21
Services billed
140
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Alzheimer's or dementia | 75% | |
| High blood pressure | 67% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
48 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.